Literature DB >> 16492797

Treatment of schizophrenia negative symptoms: future prospects.

Stephen M Erhart1, Stephen R Marder, William T Carpenter.   

Abstract

New findings from neuroscience, genetics, and experimental psychology have emerged that provide alternative explanations of many negative symptoms. We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16492797      PMCID： PMC2632230          DOI： 10.1093/schbul/sbj055

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


  30 in total

1.  Clinical profile of an atypical antipsychotic: risperidone.

Authors:  John M Davis; Nancy Chen
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

2.  Positive and negative symptoms and and adjustment in severely mentally ill outpatients.

Authors:  D Schuldberg; D M Quinlan; W Glazer
Journal:  Psychiatry Res       Date:  1999-02-22       Impact factor: 3.222

3.  Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.

Authors:  Richard B Rosse; Stephen I Deutsch
Journal:  Clin Neuropharmacol       Date:  2002 Sep-Oct       Impact factor: 1.592

Review 4.  Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia.

Authors:  John Lauriello; Rhoshel Lenroot; Juan R Bustillo
Journal:  Psychiatr Clin North Am       Date:  2003-03

5.  Odor identification, eye tracking and deficit syndrome schizophrenia.

Authors:  Dolores Malaspina; Eliza Coleman; Raymond R Goetz; Jill Harkavy-Friedman; Cheryl Corcoran; Xavier Amador; Scott Yale; Jack M Gorman
Journal:  Biol Psychiatry       Date:  2002-05-15       Impact factor: 13.382

6.  Oxytocin and vasopressin as candidate genes for psychiatric disorders: lessons from animal models.

Authors:  L J Young
Journal:  Am J Med Genet       Date:  2001-01-08

7.  Components of the smooth pursuit function in deficit and nondeficit schizophrenia.

Authors:  L Elliot Hong; Matthew T Avila; Helene Adami; Amie Elliot; Gunvant K Thaker
Journal:  Schizophr Res       Date:  2003-09-01       Impact factor: 4.939

Review 8.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia.

Authors:  Alessandro Lenzi; Elisabetta Maltinti; Enzo Poggi; Lazzerini Fabrizio; Elisabetta Coli
Journal:  Clin Neuropharmacol       Date:  2003 Nov-Dec       Impact factor: 1.592

10.  Bipolar II with and without cyclothymic temperament: "dark" and "sunny" expressions of soft bipolarity.

Authors:  Hagop S Akiskal; Elie G Hantouche; Jean François Allilaire
Journal:  J Affect Disord       Date:  2003-01       Impact factor: 4.839
View more
  44 in total

1.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

2.  Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment.

Authors:  Joseph Parks; Alan Radke; George Parker; May-Ellen Foti; Robert Eilers; Mary Diamond; Dale Svendsen; Rajiv Tandon
Journal:  Schizophr Bull       Date:  2008-04-02       Impact factor: 9.306

Review 3.  Anhedonia in schizophrenia.

Authors:  Daniel H Wolf
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

4.  Screening for negative symptoms: preliminary results from the self-report version of the Clinical Assessment Interview for Negative Symptoms.

Authors:  Stephanie G Park; Katiah Llerena; Julie M McCarthy; Shannon M Couture; Melanie E Bennett; Jack J Blanchard
Journal:  Schizophr Res       Date:  2012-01-21       Impact factor: 4.939

5.  First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors.

Authors:  Steffen B Schulz; Karin E Heidmann; Arpad Mike; Zin-Juan Klaft; Uwe Heinemann; Zoltan Gerevich
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

6.  Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis.

Authors:  Chuan Shi; Xin Yu; Eric F C Cheung; David H K Shum; Raymond C K Chan
Journal:  Psychiatry Res       Date:  2013-12-21       Impact factor: 3.222

7.  Drug discovery in psychiatric illness: mining for gold.

Authors:  Greg I Elmer; Neri Kafkafi
Journal:  Schizophr Bull       Date:  2009-03-18       Impact factor: 9.306

8.  Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis.

Authors:  Ann Faerden; Elizabeth Ann Barrett; Ragnar Nesvåg; Svein Friis; Arnstein Finset; Stephen R Marder; Joseph Ventura; Ole A Andreassen; Ingrid Agartz; Ingrid Melle
Journal:  Psychiatry Res       Date:  2013-03-13       Impact factor: 3.222

9.  Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task.

Authors:  Daniel Scott; Jane R Taylor
Journal:  Behav Brain Res       Date:  2013-11-14       Impact factor: 3.332

10.  The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms.

Authors:  Katiah Llerena; Stephanie G Park; Julie M McCarthy; Shannon M Couture; Melanie E Bennett; Jack J Blanchard
Journal:  Compr Psychiatry       Date:  2013-01-22       Impact factor: 3.735
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.